


CLAIMS

What is claimed is:

5 (1) A compound of formula I



wherein

10 R<sup>1</sup> is selected from hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

15 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>6</sup> are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, and alkanoyloxy of 2 to 6 carbon atoms; and

R<sup>5</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

X is CR<sup>6</sup> or N;

20 A dotted line represents an optional double bond;

(O) represents optional oxidation; and

n is an integer 0, 1 or 2;

or a pharmaceutically acceptable salt thereof

25 (2) A compound of Claim 1 wherein R<sup>1</sup> is hydrogen.

(3) A compound of Claim 1 wherein R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen, halogen, and cyano.

(4) A compound of Claim 1 wherein R<sup>5</sup> is hydrogen or lower alkyl.

(5) A compound of Claim 1 wherein X is CR<sup>6</sup>.

5 (6) A compound of Claim 5 wherein R<sup>6</sup> is hydrogen, halogen or cyano.

(7) A compound of Claim 1 in which R<sup>1</sup> is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is hydrogen, hydroxy, halo, cyano, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of 10 one to six carbon atoms or alkoxy of one to six carbon atoms; R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, and alkoxy of one to six carbon atoms; n is an integer 0 or 1; or a pharmaceutically acceptable salt thereof.

15 (8) A compound of Claim 1 in which R<sup>1</sup> is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is hydrogen, hydroxy or alkoxy of one to six carbon atoms, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen, halo and cyano, R<sup>5</sup> is hydrogen, X is CR<sup>6</sup>, n is 0, and the dotted line represents a double bond; or a pharmaceutically acceptable salt thereof.

20 (9) A compound of Claim 7 wherein R<sup>6</sup> is hydrogen, halo or cyano.


(10) The compound of Claim 1 which is 3-[(4-(1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-2,3-dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.

25 (11) The compound of Claim 1 which is 3-[(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)methyl]-2,3-dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.

30 (12) The compound of Claim 1 which is 3-{1-[2,3-dihydro[1,4]dioxino[2,3-b]pyridin-3-yl)methyl]-1,2,3,6-tetrahydro-4-pyridinyl}-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.

(13) The compound of Claim 1 which is 3-{[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}-2,3-dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.

5 (14) A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol 10 addiction, and sexual dysfunction which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I



wherein

15  $R^1$  is selected from hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon 20 atoms;

$R^2$ ,  $R^3$ ,  $R^4$  and  $R^6$  are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, and alkanoyloxy of 2 to 6 carbon atoms; and

$R^5$  is hydrogen or alkyl of 1 to 6 carbon atoms;

25  $X$  is  $CR^6$  or  $N$ ;

A dotted line represents an optional double bond;

(O) represents optional oxidation; and

$n$  is an integer 0, 1 or 2;


or a pharmaceutically acceptable salt thereof.

(15) The method of Claim 13 wherein the condition is depression.

(16) The method of Claim 13 wherein the condition is obsessive compulsive disorder, panic attacks, generalized anxiety disorder or social anxiety disorder.

(17) The method of Claim 13 wherein the subject is a human.

(18) A pharmaceutical composition comprising a compound of formula I



wherein

15      R<sup>1</sup> is selected from hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

20      R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>6</sup> are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, and alkanoyloxy of 2 to 6 carbon atoms; and

25      R<sup>5</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

      X is CR<sup>6</sup> or N;

      A dotted line represents an optional double bond;

      (O) represents optional oxidation; and

      n is an integer 0, 1 or 2;

      or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.